A condition previously known as polycystic ovary syndrome (PCOS) is being referred to as polyendocrine metabolic ovarian syndrome (PMOS) in some reports. The name change is seen as a potential step towards improving diagnosis and care, with some outlets suggesting that more comprehensive approaches, including integrated care, are needed to manage the condition. The impact of the name change on diagnosis, treatment, and patient care is still being discussed, with some reports highlighting potential new treatment options.